Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2024
Business Overview: Amgen is a global biotechnology pioneer operating in a single segment: human therapeutics. The company discovers, develops, manufactures, and delivers innovative medicines. A significant development in the reporting period is the ongoing integration of Horizon Therapeutics plc, acquired on October 6, 2023, which added first-in-class medicines for rare, autoimmune, and severe inflammatory diseases to Amgen's portfolio.
Key Financial Metrics
| Metric (in millions, except per share) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Total Revenues | $8,388 | $6,986 | $15,835 | $13,091 |
| Product Sales | $8,041 | $6,683 | $15,159 | $12,529 |
| Operating Income | $1,909 | $2,684 | $2,900 | $4,605 |
| Net Income | $746 | $1,379 | $633 | $4,220 |
| Diluted EPS | $1.38 | $2.57 | $1.17 | $7.86 |
| Operating Cash Flow (YTD) | $3,148 (2024) vs $5,173 (2023) | |||
| Cash and Equivalents (End of Period) | $9,301 | |||
| Total Debt (Carrying Value) | $62,645 |
Margins (YTD 2024 vs YTD 2023):
- Operating Margin: 18.3% (2024) vs 35.2% (2023)
- Net Profit Margin: 4.0% (2024) vs 32.2% (2023)
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 20% in Q2 and 21% YTD compared to the prior year. This growth was driven primarily by volume increases (26% in Q2) and the inclusion of Horizon Therapeutics products (contributing $1.1 billion in Q2 and $2.0 billion YTD). Growth was partially offset by net selling price declines of 3% in Q2 and 2% YTD.
- Profitability Decline: Net income decreased 46% in Q2 and 85% YTD. The significant drop in YTD 2023 net income was due to a one-time $1.2 billion unrealized gain on the BeiGene investment resulting from a change in accounting method. In contrast, 2024 results reflect unrealized losses on strategic equity investments (BeiGene and Neumora) totaling $714 million YTD.
- Expense Increases: Operating expenses rose 51% in Q2 and 52% YTD. This was primarily driven by higher amortization of Horizon acquisition-related intangible assets and increased R&D and SG&A expenses associated with the acquired business.
- Product Performance:
- Growers: Repatha (+25% Q2), TEPEZZA (new acquisition), KRYSTEXXA (new acquisition), EVENITY (+39% Q2), and BLINCYTO (+28% Q2).
- Decliners: ENBREL (-15% Q2) due to lower net selling prices; Otezla (-9% Q2) due to price declines and unfavorable sales deductions.
- Debt Management: Amgen repaid $1.4 billion of 3.625% notes due in 2024 and spent $410 million to extinguish other debt, resulting in a $133 million gain on extinguishment.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management expects product sales growth from Horizon products and volume growth from other brands to be partially offset by net selling price declines for the remainder of 2024. Capital allocation priorities include debt reduction, dividends, and stock repurchases ($7.0 billion authorization remaining).
- Unusual Items:
- Equity Investment Volatility: Significant unrealized losses on BeiGene and Neumora investments impacted "Other (expense) income, net."
- Tax Payments: Operating cash flow decreased YTD due to timing of payments to the IRS, including $1.5 billion in repatriation taxes and an $800 million advance deposit.
- Risks and Contingencies:
- IRS Tax Dispute: Amgen is contesting IRS notices for tax years 2010-2015 in U.S. Tax Court, involving potential additional federal taxes of approximately $8.7 billion plus interest and penalties. Trial is scheduled for November 2024.
- Patent Litigation: Ongoing disputes regarding Repatha (European patent revoked by UPC), Prolia/XGEVA (biosimilar litigation with Celltrion), and ABP 938 (Regeneron injunction motion).
- Regulatory/Pricing: The Inflation Reduction Act (IRA) mandates Medicare price setting starting in 2026, which has already set a price for ENBREL. State-level Prescription Drug Affordability Boards (PDABs) and commercial payer actions continue to exert pricing pressure.
- Cybersecurity: Recent vendor data breaches and a global IT outage in July 2024 highlighted risks to operations, though impacts were deemed immaterial.
Investor Verification Checklist
- Horizon Integration: Verify the realization of synergies and the trajectory of Horizon product sales (TEPEZZA, KRYSTEXXA, UPLIZNA) against initial projections.
- Equity Investment Valuation: Monitor the fair value of BeiGene and Neumora holdings, as fluctuations significantly impact reported net income and "Other income/expense."
- IRS Litigation Outcome: Track the November 2024 Tax Court trial regarding the 2010-2015 tax dispute, which poses a potential multi-billion dollar liability.
- ENBREL Pricing Impact: Assess the financial impact of the CMS-set Medicare price for ENBREL effective January 1, 2026, and potential biosimilar competition.
- Debt Reduction Strategy: Confirm the pace of debt repayment and the utilization of the remaining $7.0 billion stock repurchase authorization.